.jpeg)
2026-09-15 07:24:01
In September 2026, the FDA approved Scholar Rock’s Isembyld (apitegromab-mstn) for Spinal Muscular Atrophy (SMA). As the first therapy targeting skeletal muscle, it offers a novel combination approach alongside SMN2-directed therapies for patients aged 2 and older.
2026-09-14 03:57:21
Progression on enzalutamide does not mean no options. mCRPC follow-up uses HRR/BRCA testing for PARP inhibitors, PSMA PET for lutetium-177, and chemotherapy history plus bone/visceral disease for docetaxel or cabazitaxel.
2026-09-14 03:36:10
Ceritinib is an oral ALK tyrosine kinase inhibitor for validated ALK-rearranged locally advanced or metastatic non-small cell lung cancer. Usual 450mg once daily with food, with active management of diarrhea, hepatotoxicity, hyperglycemia, and QT prolongation.
2026-09-14 03:29:24
Acalabrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma is assessed by age, stage, TP53/17p status, prior therapy, and relapse. Long-term data support progression-free survival and durable disease control rather than a fixed “added years” estimate.
2026-09-14 03:25:01
Bosutinib is used for Ph+ chronic myeloid leukemia. Symptom change in a few days does not reflect efficacy. Response is tracked by CBC, BCR-ABL quantification, and cytogenetics; molecular remission often takes months, with mutation retesting for T315I/V299L.
2026-09-14 03:20:04
Bedaquiline is used only in combination for drug-resistant tuberculosis. The classic course is about 24 weeks, while all-oral regimens may run 6 or 9 months; complex resistance can be extended after specialist review based on cultures, susceptibility, and safety.
2026-09-14 03:16:19
Acalabrutinib is usually 100mg twice daily for CLL/SLL monotherapy or with obinutuzumab, and for transplant-ineligible newly diagnosed MCL with bendamustine plus rituximab. This guide simplifies dosing, toxicity breaks, and interactions.
2026-09-14 03:09:28
Enzalutamide commonly causes fatigue, musculoskeletal pain, dizziness, and hot flashes, with attention also needed for hypertension, falls, fractures, seizure, PRES, and ischemic heart disease. This guide covers tiered management and red-flag symptoms.
2026-09-14 03:06:37
Bosutinib is a BCR-ABL and Src-family tyrosine kinase inhibitor for newly diagnosed and resistant/intolerant Philadelphia chromosome-positive chronic myeloid leukemia, covering chronic, accelerated, blast phases and pediatric chronic-phase use.
2026-09-10 03:33:16
Tamoxifen is a long-established endocrine therapy for breast cancer. Long-term use requires awareness of venous thromboembolism and endometrial abnormalities. This article outlines key adverse effects and at-risk populations.
2026-09-10 03:00:52
Worsening symptoms or declining cardiac function during acoramidis treatment for ATTR-CM should not be directly labeled as drug resistance. This article explains the mechanism, proper assessment methods, and dosing compliance.
2026-09-10 02:56:36
Lorlatinib has only one formal contraindication (prohibited co-administration with strong CYP3A inducers), but six major safety risks require close attention, including CNS effects, dyslipidemia, and interstitial lung disease.
